David B. Zhen

1.1k total citations
40 papers, 646 citations indexed

About

David B. Zhen is a scholar working on Oncology, Surgery and Cancer Research. According to data from OpenAlex, David B. Zhen has authored 40 papers receiving a total of 646 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 11 papers in Surgery and 11 papers in Cancer Research. Recurrent topics in David B. Zhen's work include Pancreatic and Hepatic Oncology Research (19 papers), Cancer Genomics and Diagnostics (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers). David B. Zhen is often cited by papers focused on Pancreatic and Hepatic Oncology Research (19 papers), Cancer Genomics and Diagnostics (11 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (10 papers). David B. Zhen collaborates with scholars based in United States, Japan and Poland. David B. Zhen's co-authors include Gloria M. Petersen, Mark M. Zalupski, Vaibhav Sahai, Paul Swiecicki, Steven R. Zeldenrust, Michelle L. Mauermann, Kent A. Griffith, Morie A. Gertz, Angela Dispenzieri and Michael Goggins and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Cancer.

In The Last Decade

David B. Zhen

35 papers receiving 634 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David B. Zhen United States	13	432	276	227	156	83	40	646
Masafumi Inokuchi Japan	16	241 0.6×	178 0.6×	210 0.9×	114 0.7×	73 0.9×	61	663
Zhen-Hai Lu China	15	462 1.1×	127 0.5×	154 0.7×	182 1.2×	97 1.2×	28	614
Malti Kshirsagar United States	9	218 0.5×	201 0.7×	176 0.8×	94 0.6×	151 1.8×	9	603
A. Reinacher-Schick Germany	11	441 1.0×	175 0.6×	149 0.7×	93 0.6×	146 1.8×	46	636
Yunxia Zhu China	16	330 0.8×	446 1.6×	473 2.1×	159 1.0×	112 1.3×	55	907
Luísa Matos do Canto Brazil	15	214 0.5×	286 1.0×	187 0.8×	58 0.4×	61 0.7×	34	521
John T. Chow United States	8	201 0.5×	264 1.0×	122 0.5×	189 1.2×	90 1.1×	10	599
Bo Young Oh South Korea	17	456 1.1×	222 0.8×	184 0.8×	182 1.2×	173 2.1×	54	794
Soo-Han Jun South Korea	12	367 0.8×	246 0.9×	150 0.7×	229 1.5×	125 1.5×	15	639

Countries citing papers authored by David B. Zhen

Since Specialization

Citations

This map shows the geographic impact of David B. Zhen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Zhen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Zhen more than expected).

Fields of papers citing papers by David B. Zhen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Zhen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Zhen. The network helps show where David B. Zhen may publish in the future.

Co-authorship network of co-authors of David B. Zhen

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Zhen. A scholar is included among the top collaborators of David B. Zhen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Zhen. David B. Zhen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2025). Effect of baseline geriatric and quality of life assessments on treatment outcomes in ECOG-ACRIN EA2186 (GIANT): A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer.. Journal of Clinical Oncology. 43(4_suppl). 676–676.

King, Gentry Teng, Kelsey K. Baker, Andrew L. Coveler, et al.. (2025). Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers.. Journal of Clinical Oncology. 43(4_suppl). 594–594. 1 indexed citations

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2024). A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.. Journal of Clinical Oncology. 42(16_suppl). 4003–4003. 4 indexed citations

Sahai, Vaibhav, Kent A. Griffith, David B. Zhen, et al.. (2024). Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04).. Journal of Clinical Oncology. 42(16_suppl). 4116–4116. 2 indexed citations

Chiorean, E. Gabriela, Aude G. Chapuis, Andrew L. Coveler, et al.. (2024). Abstract A003: Preliminary safety results from a phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T cell receptor (TCR) (FH-TCR TMSLN) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDA). Cancer Research. 84(2_Supplement). A003–A003.

King, Gentry Teng, R J Berg, Melissa C. Stoppler, et al.. (2024). Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.. Journal of Clinical Oncology. 42(3_suppl). 557–557. 1 indexed citations

Zhen, David B., Anna Moseley, E. Gabriela Chiorean, et al.. (2024). SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC).. Journal of Clinical Oncology. 42(16_suppl). TPS4201–TPS4201.

King, Gentry Teng, Stacey A. Cohen, E. Gabriela Chiorean, et al.. (2023). 114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers. Annals of Oncology. 34. S225–S225. 4 indexed citations

Griffith, Kent A., David B. Zhen, Chandan Kumar‐Sinha, et al.. (2023). Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04). Clinical Cancer Research. 29(13). 2394–2400. 18 indexed citations

10.

Zhen, David B., et al.. (2023). The role of molecular testing in pancreatic cancer. Therapeutic Advances in Gastroenterology. 16. 1108354432–1108354432. 7 indexed citations

11.

Dotan, Efrat, Paul J. Catalano, Leon Lenchik, et al.. (2023). The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients. Journal of Geriatric Oncology. 14(3). 101474–101474. 11 indexed citations

12.

He, Aiwu Ruth, Vikas Gupta, Ludovic Evesque, et al.. (2023). 102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study. Annals of Oncology. 34. S220–S220.

13.

Bouattour, Mohamed, Juan W. Valle, Arndt Vogel, et al.. (2023). Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.. Journal of Clinical Oncology. 41(4_suppl). 531–531. 13 indexed citations

14.

Zhen, David B., Ramya Thota, Dong Geng, et al.. (2023). A phase 1, open-label, dose escalation and expansion, multicenter study of claudin 18.2-targeted chimeric antigen receptor T-cells in patients with unresectable, locally advanced, or metastatic gastric, gastroesophageal junction, esophageal, or pancreatic adenocarcinoma.. Journal of Clinical Oncology. 41(4_suppl). TPS480–TPS480. 5 indexed citations

15.

Zhen, David B., Martin C. Whittle, Paul S. Ritch, et al.. (2022). Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001.. Journal of Clinical Oncology. 40(4_suppl). 576–576. 15 indexed citations

16.

Bekaii‐Saab, Tanios, Sanggu Kim, Suneel D. Kamath, et al.. (2021). 1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress). Annals of Oncology. 32. S1073–S1074. 2 indexed citations

17.

Pratt, Erica D., Robert W. Cowan, Sara L. Manning, et al.. (2019). Multiplex Enrichment and Detection of Rare KRAS Mutations in Liquid Biopsy Samples using Digital Droplet Pre-Amplification. Analytical Chemistry. 91(12). 7516–7523. 26 indexed citations

18.

Zhen, David B., et al.. (2018). Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies. Journal of Oncology Pharmacy Practice. 25(4). 980–986. 4 indexed citations

19.

Zhen, David B., Kent A. Griffith, Kevin Camphausen, et al.. (2016). A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 34(6). 733–739. 27 indexed citations

20.

Zhen, David B., Kari G. Rabe, Steven Gallinger, et al.. (2014). BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genetics in Medicine. 17(7). 569–577. 203 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact